Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.40 |
| ▸ | MTOR | P42345 | 5/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 2/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30107632 | 1.00 | KDM4E (0.44) | KDM4EPIK3CAMTORPIK3CBMBOAT4 | |
| SCHEMBL13674714 | 0.85 | KDM4E (0.48) | KDM4EPIK3CAMTORPIK3CBMBOAT4 | |
| SCHEMBL27537444 | 0.83 | GRM4 (0.41) | KDM4EGRM4FGFR1 | |
| SCHEMBL10196960 | 0.79 | KDM4E (0.44) | KDM4EPIK3CAMTORPIK3CBPIK3CD | |
| SCHEMBL27282962 | 0.77 | JUN (0.40) | MBOAT4 | |
| SCHEMBL6936291 | 0.75 | KDM4E (0.55) | KDM4EPIK3CAMTORPIK3CBPIK3CD | |
| SCHEMBL3186975 | 0.75 | NFKB1 (0.43) | MBOAT4 | |
| SCHEMBL31200389 | 0.75 | MBOAT4 (0.40) | KDM4EMBOAT4 | |
| SCHEMBL30519898 | 0.75 | MBOAT4 (0.35) | MBOAT4 | |
| SCHEMBL15271570 | 0.75 | MBOAT4 (0.35) | MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-20230242494-A1 | MALONITRILE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242494-A1 | MALONITRILE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242494-A1 | MALONITRILE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-4153577-A1 | NEW MALONITRILE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| CN-115551837-A | Novel malononitrile derivatives | 豪夫迈·罗氏有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-3475285-B1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2022-02-08 | — | — | US | disclosed |
| WO-2021233854-A1 | NEW MALONITRILE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-25 | — | — | WO | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2118087-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-11-18 | — | — | EP | disclosed |
| CN-101389622-A | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG (CH) | 2009-03-18 | — | — | CN | disclosed |
| CN-101384586-A | PI-3 kinase inhibitors and methods of use thereof | NOVARTIS AG (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | KDM4E 3762/4885PIK3CA 1017/4885MTOR 985/4885 |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | MTOR, RPTOR, RICTOR | KDM4E 2910/4885PIK3CA 20/4885MTOR 1/4885 |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | KDM4E 3148/4885PIK3CA 5/4885MTOR 64/4885 |
| US-20230242494-A1 | MALONITRILE DERIVATIVES | MAL2, ME1, C5 | KDM4E 3238/4885PIK3CA 3369/4885MTOR 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.